The emerging evidence suggests that patients who develop COVID-19 complications have an abnormal immune response [92], which includes lymphocytopenia (in ~83%), thrombocytopenia (in ~36%), leukopenia (in ~33%), and elevated levels of c-reactive protein (CRP, in ~58%) [93,94]. This evidence concerns the gene CRP and lymphopenia.